Reports Q4 revenue $60.01M, consensus $58.54M. “The Xeris team executed an exceptional 2024 with record revenue topping $203 million,” said John Shannon, Xeris’ CEO. “The continued momentum of our commercial business, our exciting pipeline, along with our unrelenting focus on execution will enable Xeris to create even more value for patients and shareholders.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XERS:
- XERS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Xeris Pharmaceuticals Appoints New Chief Medical Officer
- Xeris Biopharma CEO Ken Johnson to retire, Anh Nguyen to succeed
- Biotech Alert: Searches spiking for these stocks today
- Xeris Biopharma raises FY24 revenue view to $203M from $198M-$202M